Blake has over a decade of experience writing for the web, with a focus on mobile phones, where he covered the smartphone boom of the 2010s and the broader tech scene. When he's not in front of a ...

The United States is on track to see negative net migration for the first time in at least five decades, according to CNN, as President Donald J. Trump fulfills his promise to end the migrant invasion ...

Microsoft released an emergency patch for its ASP.NET Core to fix a high-severity vulnerability that allows unauthenticated attackers to gain SYSTEM privileges on devices that use the Web development ...

Microsoft has released out-of-band (OOB) security updates to patch a critical ASP.NET Core privilege escalation vulnerability. The security flaw (tracked as CVE-2026-40372) was found in the ASP.NET ...

SunZia has quietly begun sending enormous amounts of wind power to California, as President Donald Trump works to thwart the wind industry. The largest renewable energy project ever built in the ...

The United States has achieved a historic turnaround on immigration, with net migration falling across every single metropolitan area in the country last year. It’s yet another major victory for ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...